{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:02:30Z","timestamp":1776438150344,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jjcc.2021.04.014","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T07:03:37Z","timestamp":1621839817000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of tolvaptan response and its impact on the outcome for patients with heart failure"],"prefix":"10.1016","volume":"78","author":[{"given":"Yasuhiro","family":"Hitomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nagatomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Yukino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yumita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risako","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Toya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Yada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2021.04.014_bib0001","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.319","article-title":"Heart failure as a general pandemic in Asia","volume":"17","author":"Shimokawa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008687","article-title":"9-Year trend in the management of acute heart failure in Japan: a report from the national consortium of acute heart failure registries","volume":"7","author":"Shiraishi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0003","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1253\/circj.CJ-18-1087","article-title":"Prognostic impact of previous hospitalization in acute heart failure patients","volume":"83","author":"Akita","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0004","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0005","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0006","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1517\/14656566.2011.567267","article-title":"Tolvaptan for the treatment of heart failure: a review of the literature","volume":"12","author":"Ambrosy","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12872-017-0598-y","article-title":"Effects of tolvaptan in patients with acute heart failure: a systematic review and meta-analysis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0008","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1536\/ihj.18-119","article-title":"Effects of tolvaptan on volume overload in patients with heart failure","volume":"59","author":"Kinugawa","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0009","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1536\/ihj.16-438","article-title":"Mechanisms of diuresis for acute decompensated heart failure by tolvaptan","volume":"58","author":"Nomoto","year":"2017","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment results from the K-STAR Study","volume":"82","author":"Inomata","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0013","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","article-title":"Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction prospective randomized controlled study","volume":"81","author":"Tamaki","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0014","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5582\/ddt.2018.01007","article-title":"Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease","volume":"12","author":"Ono","year":"2018","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1536\/ihj.16-625","article-title":"Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease","volume":"59","author":"Nakano","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14740\/jocmr3671","article-title":"Renoprotective benefit of tolvaptan in acute decompensated heart failure patients with loop diuretic-resistant status","volume":"11","author":"Yamamoto","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0017","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","article-title":"Diuretic response in acute heart failure: clinical characteristics and prognostic significance","volume":"35","author":"Valente","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0018","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00392-017-1122-1","article-title":"Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction","volume":"106","author":"Matsue","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fcvm.2020.00123","article-title":"Prognostic value of N-terminal pro-B-type natriuretic peptide and glomerular filtration rate in patients with acute heart failure","volume":"7","author":"Wang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2020.03.077","article-title":"Clinical significance of diastolic late mitral annular velocity in heart failure with preserved ejection fraction","volume":"316","author":"Oike","year":"2020","journal-title":"Int J Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.jjcc.2021.04.014_bib0022","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0024","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1536\/ihj.15-491","article-title":"Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin","volume":"57","author":"Kadota","year":"2016","journal-title":"Int Heart J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0026","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00380-015-0775-9","article-title":"Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease","volume":"31","author":"Uemura","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0027","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0028","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0029","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","article-title":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease","volume":"77","author":"Imamura","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0030","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","article-title":"Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure","volume":"78","author":"Imamura","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0031","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s00380-015-0780-z","article-title":"Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure","volume":"31","author":"Matsukawa","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0032","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1253\/circj.CJ-19-0158","article-title":"Real-world effectiveness and tolerability of tolvaptan in patients with heart failure final results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study","volume":"83","author":"Kinugawa","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0033","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2007.08.053","article-title":"Malignant link between chronic heart failure and acute cardiac decompensation in patients with persistently increased serum concentrations of cardiac troponin","volume":"126","author":"Sato","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0034","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.04.014_bib0035","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1253\/circj.CJ-19-0220","article-title":"First hospitalization tells us everything about heart failure","volume":"83","author":"Kinugawa","year":"2019","journal-title":"Circ J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508721001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508721001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:05:34Z","timestamp":1760274334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508721001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0914508721001118"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2021.04.014","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of tolvaptan response and its impact on the outcome for patients with heart failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2021.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}